Mexiletine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Mexiletine: From Ventricular Arrhythmia to Headache Disorder
One-Sentence Summary
Mexiletine is a Class IB antiarrhythmic drug that blocks voltage-gated sodium (Nav) channels, originally used for ventricular arrhythmias and recognised off-label for neuropathic pain and myotonia. Across the 10 TxGNN-predicted indications evaluated in this pack, headache disorder (including trigeminal autonomic cephalalgias, SUNCT/SUNA, and refractory chronic daily headache) carries the strongest real-world evidence, with 0 registered clinical trials but 7 publications—several citing Mexiletine by name—supporting this repurposing direction. Top-ranked predictions (hypertrichosis, NSIAD, Dandy-Walker malformation) were assessed as likely knowledge-graph false positives; headache disorder (TxGNN rank #10) is the most actionable candidate in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ventricular arrhythmia (inferred from drug class and literature; no India market data on file) |
| Predicted New Indication (Most Actionable) | Headache disorder (SUNCT / SUNA / refractory chronic daily headache) |
| TxGNN Prediction Score | 99.48% (rank #10 of ~18,000 diseases) |
| Evidence Level | L3 — observational studies and direct case series with Mexiletine |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why rank #10 is featured instead of rank #1: TxGNN ranks #1–5 (hypertrichosis, nephrogenic syndrome of inappropriate antidiuresis, Ambras syndrome, periodontal malformation syndrome, Dandy-Walker malformation) all scored L5 / Hold after mechanistic review—they reflect graph-topology artefacts with no biological plausibility or supporting evidence. The headache cluster (ranks #6 and #10) and pulmonary hypertension (rank #8) are the actionable signals in this pack. Rank #10 is highlighted here as it has the highest evidence level (L3) and direct Mexiletine-named literature.
Why is This Prediction Reasonable?
Mechanism of action: Detailed MOA data was not retrieved in this evidence pack (data gap DG002). Based on established pharmacology, Mexiletine is a use-dependent, voltage-gated sodium channel (Nav1.x) blocker belonging to the Class IB antiarrhythmic category. It is structurally and mechanistically homologous to lidocaine—both share a 2,6-dimethylaniline core—differing primarily in oral bioavailability, which makes Mexiletine a practical oral successor to IV lidocaine in chronic management settings.
Connecting cardiac arrhythmia to headache: Trigeminal autonomic cephalalgias (TACs)—SUNCT, SUNA, and cluster headache—involve paroxysmal, high-frequency firing of the trigeminocervical complex, a neurophysiological pattern mechanistically analogous to cardiac ectopic discharge. Intravenous lidocaine has documented acute efficacy in refractory TACs; Mexiletine’s oral bioavailability makes it a logical maintenance agent after IV lidocaine induction. Additionally, cortical spreading depression (CSD), the electrophysiological substrate of migraine aura, depends on Na⁺/K⁺ flux imbalance that Nav blockade can attenuate—a mechanism shared with topiramate, which partially inhibits Na⁺ channels and is approved for migraine prophylaxis.
Supporting the prediction: Multiple published case series (PMIDs 20425204, 18793209, 6938859) directly document Mexiletine use in headache disorders. The mechanistic overlap between cardiac and neuronal Nav channels provides a biologically coherent rationale that is not present in the top-ranked predictions. The primary evidence gap is the absence of formal randomised trials, not a question of biological plausibility.
Clinical Trial Evidence
Currently no related clinical trials are registered for Mexiletine in headache disorder.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20425204 | 2010 | Prospective Case Series | Current Pain and Headache Reports | Mexiletine and IV lidocaine as Class IB Nav blockers in TAC management; directly reviews evidence for oral mexiletine in SUNCT/SUNA as maintenance therapy after IV lidocaine induction |
| 18793209 | 2008 | Case Series (n=9) | Headache | Mexiletine used in 9 patients with refractory chronic daily headache; describes clinical outcomes and tolerability in a difficult-to-treat population |
| 33361408 | 2021 | Prospective Open-label + Single-arm Meta-analysis | J Neurol Neurosurg Psychiatry | Most rigorous available study on SUNCT/SUNA treatment landscape; provides evidence-based framework that contextualises sodium channel blockers including mexiletine |
| 6938859 | 1981 | Case Report / Small Study | NZ Medical Journal | Early clinical observation of Mexiletine in vascular headaches; first published signal for this repurposing direction |
| 24820732 | 2014 | Review | Current Pain and Headache Reports | New daily persistent headache pathogenesis and treatment challenges; contextualises refractory headache as a candidate for Nav channel modulation |
| 40197813 | 2025 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Cochrane review confirming Mexiletine’s established efficacy in myotonia (a Nav channelopathy); validates the Nav-blocking pharmacological profile applicable to neuronal excitability disorders |
| 91699 | 1979 | Clinical Study | Kardiologiia | Original antiarrhythmic study of Mexitil (mexiletine) in ventricular arrhythmias; establishes the foundational Nav-blocking pharmacology from which all repurposing rationale derives |
India Market Information
Mexiletine is currently not marketed in India. There are no drug authorizations on file (total licenses = 0). Any prospective clinical use or study in India would require a regulatory pathway assessment—such as a new drug application, import licence, or orphan drug designation if applicable.
Safety Considerations
Drug Interactions (106 total interactions identified):
| Interacting Drug | Severity | Clinical Relevance |
|---|---|---|
| Bupropion | Major | CYP2D6 inhibition by bupropion can significantly raise mexiletine plasma levels; avoid co-administration or monitor closely with dose adjustment |
| Alosetron | Moderate | Pharmacokinetic interaction via shared metabolic pathway; monitor |
| Morphine | Moderate | Potential additive CNS and cardiac effects; monitor |
| Eliglustat | Moderate | CYP2D6 substrate; interaction risk with mexiletine |
| Rolapitant | Moderate | CYP2D6-mediated PK interaction; monitor drug levels |
| Potassium citrate / Sodium sulfate / Picosulfuric acid / PEG 3350 | Moderate | Electrolyte-related interactions; monitor cardiac and electrolyte status |
| Obeticholic acid / Glycerol phenylbutyrate | Moderate | Transporter/metabolic interactions; monitor |
| Omeprazole / Simvastatin / Prednisolone / Vancomycin | Unknown | Limited DDI data; use with caution and monitor |
The full interaction database contains 106 drugs. Only the highest-priority entries are listed above. A full DDI screen against the patient’s complete medication list is required before any clinical use.
⚠️ Key warnings and contraindications data were not available in this evidence pack (data gap DG001, severity: Blocking). Please consult the FDA, EMA, or equivalent approved package insert for complete safety information prior to any prescribing or clinical study initiation.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple case series and a prospective clinical study directly document Mexiletine’s use in refractory trigeminal autonomic cephalalgias and chronic daily headache, supported by a mechanistically coherent Nav-channel rationale analogous to its established cardiac indication. Evidence remains at L3 (no RCTs), which warrants a structured pilot study before broader clinical adoption.
To proceed, the following is needed:
- Resolve blocking safety data gap (DG001): Retrieve the full package insert warnings and contraindications before any clinical protocol is developed
- Obtain formal MOA data (DG002): Query DrugBank API to populate the mechanism of action field and strengthen the regulatory submission narrative
- India regulatory pathway: Determine whether Mexiletine can be imported and studied in India under Schedule Y / new drug application, or whether an orphan designation pathway is applicable
- Pilot study design: Design a prospective open-label pilot (n=20–30) in refractory TAC or SUNCT/SUNA patients, using IV lidocaine responder status as an enrichment criterion for patient selection
- DDI risk management plan: Complete a full drug interaction screen for all anticipated co-medications in the target headache population; note the Major interaction with Bupropion requires specific protocol exclusion criteria
- Additional signals to monitor: Pulmonary hypertension (rank #8, L5 but novel mechanistic signal via TMEM16A/lidocaine analogy, PMID 41518899) warrants a dedicated in vitro validation study before any clinical investment
This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require rigorous clinical validation before therapeutic application. — TxGNN Evidence Pack v4, data cutoff 2026-04-04
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.